Stay updated on Safety of Single Dose UB-221 in Urticaria Clinical Trial

Sign up to get notified when there's something new on the Safety of Single Dose UB-221 in Urticaria Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety of Single Dose UB-221 in Urticaria Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.2 to version 2.16.3.
    Difference
    0.1%
    Check dated 2025-06-13T00:49:12.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The web page has undergone a version update from v2.16.1 to v2.16.2, with significant content removed related to antibodies, physiological effects of drugs, and immunologic factors.
    Difference
    0.6%
    Check dated 2025-06-05T20:46:16.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-29T15:33:25.000Z thumbnail image
  4. Check
    24 days ago
    No Change Detected
  5. Check
    45 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T03:24:54.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The web page has added new sections on Immunologic Factors, Physiological Effects of Drugs, and Antibodies, Monoclonal, enhancing its core content significantly.
    Difference
    0.5%
    Check dated 2025-04-23T18:59:50.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    The page has undergone significant content changes, including the removal of detailed information about a clinical study on UB-221, which included safety and efficacy evaluations, and the addition of terms related to chronic idiopathic urticaria and immunologic factors.
    Difference
    18%
    Check dated 2025-04-16T14:21:40.000Z thumbnail image

Stay in the know with updates to Safety of Single Dose UB-221 in Urticaria Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety of Single Dose UB-221 in Urticaria Clinical Trial page.